These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19580427)

  • 1. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients.
    Slodkowska EA; Ross JS
    Expert Rev Mol Diagn; 2009 Jul; 9(5):417-22. PubMed ID: 19580427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
    Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
    Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
    J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
    Krop I; Ismaila N; Andre F; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Wolff AC; Stearns V
    J Clin Oncol; 2017 Aug; 35(24):2838-2847. PubMed ID: 28692382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial.
    Audeh W; Blumencranz L; Kling H; Trivedi H; Srkalovic G
    Acta Med Acad; 2019 Apr; 48(1):18-34. PubMed ID: 31264430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
    Dobbe E; Gurney K; Kiekow S; Lafferty JS; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(1):23-8. PubMed ID: 18159035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
    Mook S; Van't Veer LJ; Rutgers EJ; Piccart-Gebhart MJ; Cardoso F
    Cancer Genomics Proteomics; 2007; 4(3):147-55. PubMed ID: 17878518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is gene array testing to be considered routine now?
    Paik S
    Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of gene expression profiling tests on breast cancer outcomes.
    Marchionni L; Wilson RF; Marinopoulos SS; Wolff AC; Parmigiani G; Bass EB; Goodman SN
    Evid Rep Technol Assess (Full Rep); 2007 Dec; (160):1-105. PubMed ID: 18457476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
    Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
    Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
    Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
    Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multigene assays in early breast cancer: Insights from recent phase 3 studies.
    Markopoulos C; Hyams DM; Gomez HL; Harries M; Nakamura S; Traina T; Katz A
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):656-666. PubMed ID: 31706719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of the 70-gene MammaPrint profile in a Japanese population.
    Ishitobi M; Goranova TE; Komoike Y; Motomura K; Koyama H; Glas AM; van Lienen E; Inaji H; Van't Veer LJ; Kato K
    Jpn J Clin Oncol; 2010 Jun; 40(6):508-12. PubMed ID: 20110242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
    Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
    Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
    Jonsdottir K; Assmus J; Slewa A; Gudlaugsson E; Skaland I; Baak JP; Janssen EA
    PLoS One; 2014; 9(3):e90642. PubMed ID: 24599057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.
    Wittner BS; Sgroi DC; Ryan PD; Bruinsma TJ; Glas AM; Male A; Dahiya S; Habin K; Bernards R; Haber DA; Van't Veer LJ; Ramaswamy S
    Clin Cancer Res; 2008 May; 14(10):2988-93. PubMed ID: 18483364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.